Cholinergic targets in lung cancer

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    Lung cancers express an autocrine cholinergic loop in which secreted acetylcholine can stimulate tumor growth through both nicotinic and muscarinic receptors. Because activation of mAChR and nAChR stimulates growth; tumor growth can be stimulated by both locally synthesized acetylcholine as well as acetylcholine from distal sources and from nicotine in the high percentage of lung cancer patients who are smokers. The stimulation of lung cancer growth by cholinergic agonists offers many potential new targets for lung cancer therapy. Cholinergic signaling can be targeted at the level of choline transport; acetylcholine synthesis, secretion and degradation; and nicotinic and muscarinic receptors. In addition, the newly describe family of ly-6 allosteric modulators of nicotinic signaling such as lynx1 and lynx2 offers yet another new approach to novel lung cancer therapeutics. Each of these targets has their potential advantages and disadvantages for the development of new lung cancer therapies which are discussed in this review.

    Original languageEnglish (US)
    Pages (from-to)2152-2159
    Number of pages8
    JournalCurrent Pharmaceutical Design
    Volume22
    Issue number14
    DOIs
    StatePublished - Apr 1 2016

    Fingerprint

    Cholinergic Agents
    Lung Neoplasms
    Acetylcholine
    Nicotinic Receptors
    Muscarinic Receptors
    Growth
    Cholinergic Agonists
    Choline
    Nicotine
    Neoplasms
    Therapeutics

    Keywords

    • Acetylcholine
    • Cancer
    • Lynx-1
    • Muscarinic receptors
    • Nicotine
    • Nicotinic receptors

    ASJC Scopus subject areas

    • Drug Discovery
    • Pharmacology

    Cite this

    Cholinergic targets in lung cancer. / Spindel, Eliot.

    In: Current Pharmaceutical Design, Vol. 22, No. 14, 01.04.2016, p. 2152-2159.

    Research output: Contribution to journalArticle

    @article{e7ab16dc5b8946aa819535069e7d612e,
    title = "Cholinergic targets in lung cancer",
    abstract = "Lung cancers express an autocrine cholinergic loop in which secreted acetylcholine can stimulate tumor growth through both nicotinic and muscarinic receptors. Because activation of mAChR and nAChR stimulates growth; tumor growth can be stimulated by both locally synthesized acetylcholine as well as acetylcholine from distal sources and from nicotine in the high percentage of lung cancer patients who are smokers. The stimulation of lung cancer growth by cholinergic agonists offers many potential new targets for lung cancer therapy. Cholinergic signaling can be targeted at the level of choline transport; acetylcholine synthesis, secretion and degradation; and nicotinic and muscarinic receptors. In addition, the newly describe family of ly-6 allosteric modulators of nicotinic signaling such as lynx1 and lynx2 offers yet another new approach to novel lung cancer therapeutics. Each of these targets has their potential advantages and disadvantages for the development of new lung cancer therapies which are discussed in this review.",
    keywords = "Acetylcholine, Cancer, Lynx-1, Muscarinic receptors, Nicotine, Nicotinic receptors",
    author = "Eliot Spindel",
    year = "2016",
    month = "4",
    day = "1",
    doi = "10.2174/1381612822666160127114237",
    language = "English (US)",
    volume = "22",
    pages = "2152--2159",
    journal = "Current Pharmaceutical Design",
    issn = "1381-6128",
    publisher = "Bentham Science Publishers B.V.",
    number = "14",

    }

    TY - JOUR

    T1 - Cholinergic targets in lung cancer

    AU - Spindel, Eliot

    PY - 2016/4/1

    Y1 - 2016/4/1

    N2 - Lung cancers express an autocrine cholinergic loop in which secreted acetylcholine can stimulate tumor growth through both nicotinic and muscarinic receptors. Because activation of mAChR and nAChR stimulates growth; tumor growth can be stimulated by both locally synthesized acetylcholine as well as acetylcholine from distal sources and from nicotine in the high percentage of lung cancer patients who are smokers. The stimulation of lung cancer growth by cholinergic agonists offers many potential new targets for lung cancer therapy. Cholinergic signaling can be targeted at the level of choline transport; acetylcholine synthesis, secretion and degradation; and nicotinic and muscarinic receptors. In addition, the newly describe family of ly-6 allosteric modulators of nicotinic signaling such as lynx1 and lynx2 offers yet another new approach to novel lung cancer therapeutics. Each of these targets has their potential advantages and disadvantages for the development of new lung cancer therapies which are discussed in this review.

    AB - Lung cancers express an autocrine cholinergic loop in which secreted acetylcholine can stimulate tumor growth through both nicotinic and muscarinic receptors. Because activation of mAChR and nAChR stimulates growth; tumor growth can be stimulated by both locally synthesized acetylcholine as well as acetylcholine from distal sources and from nicotine in the high percentage of lung cancer patients who are smokers. The stimulation of lung cancer growth by cholinergic agonists offers many potential new targets for lung cancer therapy. Cholinergic signaling can be targeted at the level of choline transport; acetylcholine synthesis, secretion and degradation; and nicotinic and muscarinic receptors. In addition, the newly describe family of ly-6 allosteric modulators of nicotinic signaling such as lynx1 and lynx2 offers yet another new approach to novel lung cancer therapeutics. Each of these targets has their potential advantages and disadvantages for the development of new lung cancer therapies which are discussed in this review.

    KW - Acetylcholine

    KW - Cancer

    KW - Lynx-1

    KW - Muscarinic receptors

    KW - Nicotine

    KW - Nicotinic receptors

    UR - http://www.scopus.com/inward/record.url?scp=84969142117&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84969142117&partnerID=8YFLogxK

    U2 - 10.2174/1381612822666160127114237

    DO - 10.2174/1381612822666160127114237

    M3 - Article

    C2 - 26818857

    AN - SCOPUS:84969142117

    VL - 22

    SP - 2152

    EP - 2159

    JO - Current Pharmaceutical Design

    JF - Current Pharmaceutical Design

    SN - 1381-6128

    IS - 14

    ER -